APIs Business Unit
CDMO/CMO service
Nucleic acid materials BU
APIs BU focus on small molecule pharmaceutical ingredients,
is dedicated to the research and development of pharmaceutical materials. It has passed official inspections from domestic and foreign drug regulatory agencies for many times, such as China’s NMPA, US FDA, EU EDQM, Japan’s PMDA, South Korea’s MFDS, etc., and has successively obtained CEP certifificates for multiple core products
20+ years experience
CMO projects 60+
EU GMP certificate
Stable management staff 18 years+
Data encryption
Nucleic acid business unit is led by PhD team with rich pharmaceutical industry background, focusing on the independent research and
development of key raw materials and excipients of mRNA drugs and oligos, such as Cap Analog and intermediate, Nucleotide, modified
Nucleotide, Enzyme, Cationic acid(Ionizable Lipid), Phosphoramidite, and commercial production base with GMP system. Dedicated to
become the best partner of innovative nucleic acid drug field. We can provide nucleotides and modified nucleotides, the product quality
has reached the international level, and the cost is controllable, and the batch-to-batch quality is stable; provide capping materials for
mRNA synthesis to achieve efficient and economical co-transcription capping; provide LNP raw materials that meet the requirements of
the nucleic acid delivery system and the GMP production conditions; provide mRNA Cap Analog CDMO service.